Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors
Author:
- 1 June 1994
- journal article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 3 (6) , 577-595
Abstract
Future approaches to cancer chemotherapy will inevitably include ways to modulate the function of oncogenes, suppressor genes or components of mitogenic or cell cycle signal transduction. One set of likely targets for therapeutic intervention are tyrosine kinases. Over the past decade, tyrosine phosphorylation/dephosphorylation has irrefutably been shown to be intimately involved in growth regulation, mitogenesis and cell cycle progression. Many of the known tyrosine kinases are encoded for by proto-oncogenes, and transforming mutations or uncontrolled activity of these enzymes have been observed in tumours. Certain growth factors known or suspected to participate in autocrine mechanisms of tumour propagation bind to receptors having tyrosine kinase activity and there now exists a significant amount of clinical data to implicate a role for many of these enzymes in the development or progression of disease in cancer patients. Throughout the last decade many inhibitors of tyrosine kinases have been discover...Keywords
This publication has 179 references indexed in Scilit:
- Inhibition of Ret Tyrosine Kinase Activity by Herbimycin ABiochemical and Biophysical Research Communications, 1993
- Nonselective actions of herbimycin AImmunology Today, 1993
- The fibroblast growth factor and receptor multigene familiesThe Journal of Pathology, 1993
- Synergistic induction of erythroid differentiation of mouse erythroleukemia (MEL) cells by inhibitors of topoisomerases and protein tyrosine kinasesExperimental Cell Research, 1992
- Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostinsExperimental Cell Research, 1992
- Epidermal growth factor receptor expression as a prognostic indicator in breast cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of progressionBreast Cancer Research and Treatment, 1991
- Effects of herbimycin A and various SH-reagents on p60v-src kinase activity invitroBiochemical and Biophysical Research Communications, 1990
- Irreversible inhibition of v-src tyrosine kinase activity by herbimycin a and its abrogation by sulfhydryl compoundsBiochemical and Biophysical Research Communications, 1989
- Growth inhibition of human nasopharyngeal carcinoma in athymic mice by anti‐epidermal growth factor receptor monoclonal antibodiesStem Cells, 1989